First Wave BioPharma changes name to Entero Therapeutics; ticker to ENTO effective May 17

GridAI Technologies Corp.

Name change from First Wave BioPharma to Entero Therapeutics effective May 17, 2024.
Nasdaq ticker symbol changes from FWBI to ENTO at market open on May 17.
Rebranding follows recent business combination with ImmunogenX, reflecting GI-focused pipeline.
Lead asset latiglutenase for celiac disease; Phase 3 trial expected to begin early 2025.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

GridAI Technologies Corp.: Company changed its corporate name from First Wave BioPharma, Inc. to Entero Therapeutics, Inc. via amendment to Amended and Restated Certificate of Incorporation (effective 2024-05-17).

Change: charter amendment
Effective: 2024-05-17

Exact text from the filing

On May 15, 2024, First Wave BioPharma, Inc. (the “Company”) filed an amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of Delaware to change its corporate name from "First Wave BioPharma, Inc." to "Entero Therapeutics, Inc." (the "Name Change Amendment"). Pursuant ot the Name Change Amendment, this name change is effective as of May 17, 2024.

View on SEC.gov

74 governance changes filed in the last 30 days. Browse all governance changes →

GridAI Technologies Corp. filing history →

Source: SEC EDGAR

accession 0001104659-24-062263

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.